Trial Profile
A Randomized, Double-blind, Placebo Controlled Study, Designed to Investigate the Effect of Ranolazine on Left Ventricular Diastolic Function in Patients With Symptomatic AF and Preserved Ejection Function, After the Subject Has Undergone a Successful External Electrical Cardioversion
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 23 Jul 2015
Price :
$35
*
At a glance
- Drugs Ranolazine (Primary)
- Indications Atrial fibrillation; Heart failure
- Focus Therapeutic Use
- Acronyms RAD-HF
- 25 Feb 2015 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.
- 03 Jul 2013 New trial record